Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities
Net loss	$ (102,072)	$ (50,816)
Adjustments to reconcile net loss to net cash used in operating activities:
Acquired in-process research and development assets	0	8,000
Share-based compensation expense	20,409	8,224
Depreciation expense	48	15
Accretion of discounts on debt securities	(1,031)	0
Amortization of operating right-of-use assets	303	133
Non-cash interest expense	0	19
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(1,113)	(4,808)
Deposits and other long-term assets	(280)	(31)
Accounts payable	2,229	483
Accrued expenses and other current liabilities	7,127	3,565
Operating lease liabilities	(184)	(154)
Net cash used in operating activities	(74,564)	(35,370)
Cash flows from investing activities
Cash paid for acquired in-process research and development assets	0	(8,000)
Cash paid for purchase of short-term investments	(272,838)	0
Proceeds from maturity of short-term investments	20,000	0
Cash paid for purchase of property and equipment	(26)	0
Cash used in investing activities	(252,864)	(8,000)
Cash flows from financing activities
Proceeds from issuance of Series B redeemable convertible preferred shares, net of issuance costs	0	129,757
Proceeds from issuance of common stock, net	161,610	167,045
Proceeds from issuance of common stock upon stock option exercises	2,053	0
Proceeds from issuance of common stock upon ESPP purchase	320	0
Net cash provided by financing activities	163,983	296,802
Net increase in cash and cash equivalents	(163,445)	253,432
Cash and cash equivalents, beginning of period	284,309	43,728
Cash and cash equivalents, end of period	120,864	297,160
Supplemental disclosures of noncash activities
Lease liability obtained in exchange for right-of-use asset	940	0
Exchange of 45,331,483 preferred, common, and incentive shares in connection with the Conversion (Note 1)	0	224,892
Exchange of redeemable convertible noncontrolling interest to 6,470,382 shares of common stock (Note 11)	$ 0	$ 3,592